Why the study?
The relationship between cancer and subclinical atherosclerosis has been a focus of attention, prompting an evaluation of cancer's effects on functional and structural markers of subclinical atherosclerosis.
Does cancer increase functional and structural markers of subclinical atherosclerosis (IMT, PWV, FMD) compared to healthy controls?
Does cancer increase functional and structural markers of subclinical atherosclerosis (IMT, PWV, FMD) compared to healthy controls?
Cancer and its treatments are associated with increased markers of subclinical atherosclerosis (IMT and PWV), highlighting the importance of early cardiovascular prevention in oncology patients.
Cancer history may warrant vascular screening in survivors; leaves open causality and targeted intervention trials.
Objectives The relationship between cancer and subclinical atherosclerosis has always been the focus of people's attention. We conducted a systematic review and meta-analysis by evaluating the effects of cancer on functional and structural markers of subclinical atherosclerosis:intima-media thickness (IMT), pulse wave velocity (PWV), and flow-mediated vasodilation (FMD). Methods A comprehensive and systematic literature search was conducted on the internet. Sensitivity analysis, publication bias, standard mean difference (SMD), corresponding 95% confidence interval (95% CI), and subgroup analysis were performed for all relevant research indicators in the retrieved literature. Results Forty-six studies were included, including 3,729 cancer patients and 2,404 healthy controls. Cancer patients had significantly thicker IMT [SMD (95%CI) = 0.290 (0.069 to 0.511), P = 0.010] and higher PWV [SMD (95%CI) = 0.392 (0.136 to 0.647), P = 0.003] compared with healthy controls. There was no significant difference in FMD [SMD (95% CI) = −0.192 (−0.527 to 0.144), P > 0.05). After subgrouping by age, male proportion, and treatment, the analysis results of IMT ≥ 50 years old, PWV and FMD < 50 years old, male proportion ≥50%, chemotherapy group, IMT and PWV radiotherapy group, and PWV endocrine therapy group were statistically significant ( P < 0.05). There were no significant differences in other subgroup analyses, overall sensitivity analysis, and publication bias ( p < 0.05). Conclusions Cancer may promote subclinical atherosclerosis, and change the functional and structural markers of subclinical atherosclerosis such as IMT and PWV. Early intervention and prevention should be pursued.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: